Track topics on Twitter Track topics that are important to you
LONDON (Reuters) - Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.
Original Article: Oxford BioMedica wins second $100 million gene therapy contractNEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...